Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a phone app keep teens on track with sickle cell treatment?

NCT ID NCT04688411

Disease control Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This pilot trial tests whether a smartphone app called MED-Go can help adolescents and young adults with sickle cell disease take their daily hydroxyurea more consistently. Participants aged 12 to 21 will use the app for 12 weeks, and researchers will measure how often they log their doses and how usable they find the app. The goal is to see if this digital approach is practical and acceptable enough to support better medication habits and, ultimately, better health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MED-Go app, a smartphone application designed to support daily hydroxyurea adherence
What this could lead to
If the app proves practical and user-friendly, it could offer a simple digital tool to help young people with sickle cell disease stay consistent with their medication, potentially improving long-term health.
What could go wrong
This is a small pilot study focused on feasibility, not health outcomes. The app may not be engaging enough for daily use, and any benefit to disease control remains uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

36 people

The number who actually took part.

Started

Sep 2020

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 21 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 12-21 years old * Any sickle cell disease genotype * On steady state of hydroxyurea for 2 months * Own of have access to a smartphone during the study period Exclusion Criteria: * Recent hospitalizations within the past 7 days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sickle B+ thalassemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hemoglobin SC Disease sickle cell disease sickle cell-beta plus-thalassemia sickle cell-beta zero-thalassemia sickle cell-hemoglobin c disease syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sickle B+ thalassemia Sickle beta zero thalassemia Sickle cell disease Sickle cell hemoglobin C

Contacts and locations

Locations

  • Ann & Robert H Lurie Children's Hospital of Chicago

    Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.